Page 20 - TD-3-3

Tumor Discovery Immune and epigenetic therapies for TNBC

21. Perdiguero EG, Geissmann F. Identifying the infiltrators. 2009;182(8):4499-4506.
Science. 2014;344:801-802.
doi: 10.4049/jimmunol.0802740
doi: 10.1126/science.1255117
31. Gomez S, Tabernacki T, Kobyra J, Roberts P, Chiappinelli KB.
22. Huertas-Caro CA, Ramírez MA, Rey-Vargas L, et al. Tumor Combining epigenetic and immune therapy to overcome
infiltrating lymphocytes (TILs) are a prognosis biomarker cancer resistance. Semin Cancer Biol. 2020;65:99-113.
in Colombian patients with triple negative breast cancer. Sci doi: 10.1016/j.semcancer.2019.05.008
Rep. 2023;13(1):21324.
32. Bird L. MDSC metabolite stuns T cells. Nat Rev Immunol.
doi: 10.1038/s41598-023- 48300-4
2020;20:352-353.
23. Dieci MV, Radosevic-Robin N, Fineberg S, et al. Update
on tumor-infiltrating lymphocytes (TILs) in breast cancer, doi: 10.1038/s41577-020-0336-z
including recommendations to assess TILs in residual 33. Lu Z, Zou J, Li S, et al. Epigenetic therapy inhibits
disease after neoadjuvant therapy and in carcinoma in situ: metastases by disrupting premetastatic niches. Nature.
A report of the International Immuno-Oncology Biomarker 2020;579(7798):284-290.
Working Group on Breast Cancer. Semin Cancer Biol. doi: 10.1038/s41586-020-2054-x
2018;52:16-25.
34. Ge Y, Cheng D, Jia Q, Xiong H, Zhang J. Mechanisms
doi: 10.1016/j.semcancer.2017.10.003
underlying the role of myeloid-derived suppressor cells in
24. Demaria S, Volm MD, Shapiro RL, et al. Development clinical diseases: Good or bad. Immune Netw. 2021;21:e21
of tumor-infiltrating lymphocytes in breast cancer after
neoadjuvant paclitaxel chemotherapy. Clin Cancer Res. doi: 10.4110/in.2021.21.e21
2001;7(10):3025-3032. 35. Xu Z, Ji J, Xu J, et al. MiR-30a increases MDSC differentiation
doi: 10.1158/1078-0432.CCR-07-1004 and immunosuppressive function by targeting SOCS3 in
mice with B-cell lymphoma. FEBS J. 2017;284(15):2410-2424.
25. Liu S, Duan X, Xu L, et al. Optimal threshold for stromal
tumor-infiltrating lymphocytes: Its predictive and doi: 10.1111/febs.14133
prognostic value in HER2-positive breast cancer treated 36. Kajihara N, Kobayashi T, Otsuka R, et al. Tumor-derived
with trastuzumab-based neoadjuvant chemotherapy. Breast interleukin-34 creates an immunosuppressive and
Cancer Res Treat. 2015;154(2):239-249. chemoresistant tumor microenvironment by modulating
doi: 10.1007/s10549-015-3617-7 myeloid-derived suppressor cells in triple-negative breast
cancer. Cancer Immunol Immunother. 2023;72(4):851-864.
26. West NR, Milne K, Truong PT, Macpherson N, Nelson BH,
Watson PH. Tumor-infiltrating lymphocytes predict doi: 10.1007/s00262-022-03293-3
response to anthracycline-based chemotherapy in estrogen 37. Mehdizadeh R, Shariatpanahi SP, Goliaei B, Rüegg C.
receptor-negative breast cancer. Breast Cancer Res. Targeting myeloid-derived suppressor cells in combination
2011;13(6):R125. with tumor cell vaccination predicts anti-tumor immunity
doi: 10.1186/bcr3072 and breast cancer dormancy: An in silico experiment. Sci
Rep. 2023;13(1):5875.
27. Gao G, Wang Z, Qu X, Zhang Z. Prognostic value of tumor-
infiltrating lymphocytes in patients with triple-negative doi: 10.1038/s41598-023-32554-z
breast cancer: A systematic review and meta-analysis. BMC 38. Hao Z, Li R, Wang Y, Li S, Hong Z, Han Z. Landscape of
Cancer. 2020;20(1):179. myeloid-derived suppressor cell in tumor immunotherapy.
doi: 10.1186/s12885-020-6668-z Biomark Res. 2021;9(1):77.
28. Mao Y, Qu Q, Chen X, Huang O, Wu J, Shen K. The doi: 10.1186/s40364-021-00333-5
prognostic value of tumor-infiltrating lymphocytes in breast 39. Kumar S, Wilkes DW, Samuel N, et al. Δnp63-driven
cancer: A systematic review and meta-analysis. PLoS One. recruitment of myeloid-derived suppressor cells promotes
2016;11(4):e0152500. metastasis in triple-negative breast cancer. J Clin Invest.
doi: 10.1371/journal.pone.0152500 2018;128(11):5095-5109.
29. Wu Y, Yi M, Niu M, Mei Q, Wu K. Myeloid-derived doi: 10.1172/JCI99673
suppressor cells: An emerging target for anticancer 40. Nefedova Y, Fishman M, Sherman S, Wang X, Beg AA,
immunotherapy. Mol Cancer. 2022;21:184. Gabrilovich DI. Mechanism of all-trans retinoic acid effect
doi: 10.1186/s12943-022-01657-y on tumor-associated myeloid-derived suppressor cells.
Cancer Res. 2007;67(22):11021-11028.
30. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor
cells: Linking inflammation and cancer. J Immunol. doi: 10.1158/0008-5472.CAN-07-2593

Volume 3 Issue 3 (2024) 14 doi: 10.36922/td.3383